SanBio Company Limited Stock OTC Markets
Equities
SNBO.Y
US7995731004
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | -48.72% | -.--% | -.--% |
Mar. 19 | SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March | MT |
Mar. 19 | Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform | MT |
Sales 2025 * | - | Sales 2026 * | 660M 4.22M | Capitalization | 31.78B 203M |
---|---|---|---|---|---|
Net income 2025 * | -3.3B -21.06M | Net income 2026 * | -3.53B -22.55M | EV / Sales 2025 * | - |
Net Debt 2025 * | 226M 1.44M | Net Debt 2026 * | 3.03B 19.39M | EV / Sales 2026 * | 52.7 x |
P/E ratio 2025 * |
-9.44
x | P/E ratio 2026 * |
-8.84
x | Employees | 29 |
Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 71.15% |
Latest transcript on SanBio Company Limited
1 day | -48.72% | ||
3 months | -39.54% |
Managers | Title | Age | Since |
---|---|---|---|
Keita Mori
CEO | Chief Executive Officer | 56 | 13-02-26 |
Shinya Hirata
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Noboru Kotani
BRD | Director/Board Member | 67 | 13-02-28 |
Keita Mori
CEO | Chief Executive Officer | 56 | 13-02-26 |
Toru Kawanishi
CHM | Chairman | 56 | 13-02-26 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- 4592 Stock
- SNBO.Y Stock